Table 3.
Current use | Cases (n=317) | Controls (n=3150) | OR (95% CI)* | OR (95% CI), adjusted† |
PPIs with NSAIDs | 51 | 95 | 3.92 (2.40 to 6.52) | 3.12 (1.84 to 5.37) |
PPIs without NSAIDs | 97 | 560 | Reference | Reference |
PPIs with penicillins | 15 | 73 | 0.75 (0.39 to 1.39) | 0.83 (0.42 to 1.59) |
PPIs without penicillins | 133 | 582 | Reference | Reference |
PPIs with macrolides | 12 | 83 | 0.46 (0.21 to 0.89) | 0.47 (0.21 to 0.96) |
PPIs without macrolides | 136 | 572 | Reference | Reference |
PPIs with cephalosporins | 25 | 55 | 2.57 (1.43 to 4.62) | 1.88 (1.02 to 3.47) |
PPIs without cephalosporins | 123 | 600 | Reference | Reference |
PPIs with fluoroquinolones | 17 | 31 | 3.08 (1.50 to 6.38) | 2.35 (1.12 to 4.95) |
PPIs without fluoroquinolones | 131 | 624 | Reference | Reference |
*ORs of AKI for current drug combinations compared with PPIs alone were estimated using the conditional logistic regression model.
†Adjusted ORs were estimated by entering the potential confounders into the model.
AKI, acute kidney injury; NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors.